Pharma Marketing Network

OCTOBER 17, 2024

As we approach 2025, the pharmaceutical industry is witnessing a seismic shift in marketing strategies, driven by technological advancements and evolving consumer expectations. As patients become more digitally savvy, pharma companies are investing in creating seamless digital experiences that cater to their needs and preferences.

Marketing 52

Marketing Healthcare Healthcare Pharma 52

European Pharmaceutical Review

NOVEMBER 2, 2023

Sustainable biosimilar competition in Europe: can it be achieved? He added that the approval of Wezlana “could have a meaningful impact for patients managing their disease.” Stelara biosimilars in the US market The first Stelara biosimilars are expected to enter the US market in 2025. “We

Food and Drug Administration 98

Food and Drug Administration FDA Side effects Safety 98

Pharmaceutical Technology

JUNE 7, 2023

Mounjaro’s approval for obesity, particularly in the US and EU markets, means the drug is entering a significantly large market where it will have direct competition from Novo Nordisk’s Wegovy (semaglutide), which is currently the leading glucagon-like peptide-1 (GLP-1) therapy approved for obesity by both the FDA and EMA.

Leads 98

Leads Marketing FDA Sales 98

PM360

SEPTEMBER 21, 2023

This article covers some of the reasons these drugs were chosen, how the process for price negotiation will occur, and the impact for the industry and for patients. They do not have biosimilar or generic competition available in the market. However, the impact of the new law will reverberate in the industry for years to come.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

PM360

JULY 13, 2023

billion by 2025, growing at a compound annual growth rate of 6.7%. billion by 2025, growing at a compound annual growth rate of 6.7%. Solving this will require reassembling these solutions to put the patient at the center of the healthcare experience. The global healthcare IT market was valued at $280.3

Healthcare 98

Healthcare Healthcare Consulting Healthcare Provider 98

European Pharmaceutical Review

OCTOBER 31, 2024

Commitment to manufacturing the £520 million life sciences innovative manufacturing fund is very welcome, and will be crucial in helping to capture high-productivity investment” The Association of the British Pharmaceutical Industry (ABPI) backed the proposed measures to enhance life sciences competitiveness in the UK.

Manufacturing 52

Manufacturing Medical science Medicine Engineering 52

Pharmaceutical Technology

OCTOBER 31, 2022

Two categories of novel therapies stand out: cell therapies and therapies with novel MOAs, with new products in each category being forecast to launch between 2023 and 2025. However, the late-stage pipeline is seeing new companies enter the space, with intense competition for patient share driving innovation. in the US).

Marketing 59

Marketing Sales Patients Competition 59

pharmaphorum

JANUARY 10, 2023

Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. If you have to wait to extract meaning from your data then you won’t be competitive enough. “A

Marketing 98

Marketing Pharma Healthcare Healthcare 98

European Pharmaceutical Review

AUGUST 23, 2022

The regulation will be applied by 12 January 2025 and will therefore take three years to become effective in Member States (and thus to fully appreciate its impact). To achieve this objective, the regulation amends Directive 2011/24/EU on the application of patients’ rights in cross?border It introduces an evidence?based

Consulting 98

Consulting Medical Healthcare Healthcare 98

pharmaphorum

NOVEMBER 25, 2022

The Parma site, as yet only nine months into construction, is due to become operational from 2024, with FDA, IFA, and EMA approvals due to be sought for 2025. In brief, the European plan for Chiesi is in-house drug development of biologicals and rare disease targeting. The situation was reversed only 25 years ago.

Pharmaceutical 98

Pharmaceutical Manufacturing Medicine Competition 98

pharmaphorum

JANUARY 4, 2023

The intention is to streamline the process for patients wishing to access their medical records via electronic health record systems (“EHR systems”) and to facilitate the ability for researchers, innovators, and policy makers to use the data in a trusted and secure way that preserves privacy. When will it come into force?

Pharmaceutical 98

Pharmaceutical Electronics Healthcare Healthcare 98

Pharmaceutical Technology

JULY 21, 2022

The Covid-19 pandemic has demonstrated how vital patient access to quality and affordable healthcare is for patients all over the world. As part of ESG (Environmental, Social, and Governance), the social good delivered by robust healthcare systems are at the core of healthy populations. Access to medication.

Government 52

Government Healthcare Healthcare Pharma 52

pharmaphorum

SEPTEMBER 11, 2022

Results from the POETYK PSO-1 and POETYK PSO-2 showed that 59% and 54% respectively of patients treated with Sotyktu achieved 75% skin clearance, versus 35% and 40% for Otezla. “We believe Sotyktu is a breakthrough in the treatment of patients with this condition, and we’re excited about its potential in other immune-mediated diseases.”

FDA 52

FDA Marketing Sales Patients 52

Med Device Careers

JANUARY 3, 2022

The procedure may be as short as 30 minutes to several hours in duration, with typical recovery time ranging from 4-8 hours and many patients are able to go home in the same day. During this procedure the patient may be given general anesthesia, light sedation or may be fully awake but given medication to relax.

Specialization 52

Specialization Medical Engineering Healthcare 52

Medico Reach

AUGUST 30, 2022

New York Presbyterian Hospital’s ‘Patient Stories’. Healthcare advertisements that feature patient experiences can evoke powerful emotions. It hosted a campaign that highlighted the real-life experiences of patients. The highlighted blog featured personal accounts from patients, their families, and Mayo Clinic employees.

Healthcare 52

Healthcare Healthcare Marketing Medical 52

Clarivate

AUGUST 27, 2024

In addition, the improved safety profile of PFA is making the cost-benefit of ablation an easier calculation for many patients. FDA approval in the fourth quarter, with Johnson & Johnson’s Varipulse system close behind, so competition will pick up. Abbott’s Volt should join the party in early 2026.

Marketing 52

Marketing Competition FDA Electronics 52

Rep-Lite

JULY 27, 2023

In today’s fast-evolving world, the medical sales industry stands at the forefront of innovation, with medical devices playing a pivotal role in patient care and treatment. billion by 2025. Navigating Regulatory Changes and Compliance The medical device industry operates under strict regulations to ensure patient safety.

Sales 52

Sales Medical Medical sales Sales Strategy 52

Clarivate

APRIL 24, 2023

Health systems will buy or establish an insurance plan to serve as an extension of their continuum of care, a means of directing referral streams to increase revenue and securing control over clinical and formulary decisions for patients. In January 2023, VillageMD acquired Summit Health for $8.9

Healthcare 89

Healthcare Healthcare Marketing Physicians 89

Clarify Health

DECEMBER 2, 2019

The model allows Providers and risk-bearing entities to ‘directly contract’ with CMS and receive monthly capitation payments for the care of their patients. Performance years for Direct Contracting are 2021 – 2025. The program is intended to improve the patient experience by incentivizing more coordinated care.

Distribution 52

Distribution Marketing Competition Patients 52

Healthcare Success

NOVEMBER 7, 2022

They’re researching key trends that will attract new high-intent audiences, increase engagement, drive revenue, and reinforce patient loyalty in 2023. What’s more, tying specific ad campaigns to patient outcomes with traditional TV advertising can be challenging. Best-in-class healthcare marketers are already planning for next year.

Marketing 52

Marketing Media Healthcare Healthcare 52

Pharmaceutical Technology

SEPTEMBER 22, 2022

“It's very difficult in the current environment, given the pressure on the health economies to make sure that you're successful everywhere, but we really have a strong belief in the value that we're bringing, health economics-wise, patient-wise, to the overall system to tackle cardiovascular disease.”. Cardiovascular disease landscape.

Pharmaceutical 52

Pharmaceutical Marketing FDA Leads 52

Healthcare Success

SEPTEMBER 12, 2024

In this two-part series, I explore the evolution of organic and paid search, discuss its impact on your SEO strategy, and share how your healthcare organization can navigate these changes to enhance online visibility and remain competitive. First, let’s review the evolution of search and its impact on SEO. What’s Next for Search?

Engineering 62

Engineering Insurance Competition Leads 62

Clarify Health

NOVEMBER 27, 2019

This application applies to the 2021-2025 performance period. Competition is more center-stage than in previous models, including both voluntary beneficiary alignment and extra incentives for high performers. It intends to promote the delivery of integrated care for patients and a better professional experience for providers.

Government 40

Government Competition Patients 40

Clarify Health

DECEMBER 5, 2023

They will help strengthen efforts to access and analyze this valuable healthcare price data for patients and other stakeholders. CMS will require compliance with these last few elements starting January 1, 2025. On the other hand, providers can use pricing information to position themselves competitively in the market.

Healthcare 52

Healthcare Healthcare Competition Marketing 52

Clarivate

OCTOBER 10, 2022

Clarivate oncology experts share key takeaways from the 2022 ESMO Congress and their expected impact on the drug treatment landscape and patients. Positive outcomes in a key patient segment could broaden TRODELVY’s uptake in metastatic breast cancer. Market impact.

Marketing 52

Marketing Safety Patients Competition 52

PM360

AUGUST 9, 2022

Science continues to evolve rapidly, most recently delivering more complex technologies with the advent of immunotherapies, cell and gene therapies, and more platform technologies (such as CRISPR) that target diseases with niche patient subgroups. Ask: Is this component truly a competitive advantage? The Payoff Is Real.

Biopharma 69

Biopharma Marketing Healthcare Healthcare 69

Healthcare Success

OCTOBER 11, 2022

Despite this bias, patients are more than willing to pay out of pocket for the pricey healthcare products and services they value—but that is only a part of the equation. They’re looking for hospitals, health systems, and health and wellness brands that offer exceptional patient experiences from end to end.

Healthcare 62

Healthcare Healthcare Marketing Retail 62

European Pharmaceutical Review

FEBRUARY 7, 2023

From 31 January 2025, new and ongoing clinical trials in the EU must be conducted in compliance with the CTR. In addition, the devices must not present an unacceptable risk to patient and user health and safety as established in Articles 94 and 95 of the MDR. Authorisation of the clinical trial, may, however, be obtained later.

Medical 117

Medical Government Marketing Medicine 117

Healthcare Success

DECEMBER 16, 2024

We are not patient facing. Post-acute care, that's where patients go when they are discharged to typically from a hospital. And so, funny enough, we just had our planning meeting to stand up our campaigns for the first half of 2025, and we have a really nice, very simple template of you know. So, I had been on the payer side.

Marketing 52

Marketing Physicians Sales Healthcare 52

PM360

SEPTEMBER 28, 2022

Patient behavior on insulin: Part D plans will have limited opportunity to adjust strategy for 2023, given bids are locked in. Behavioral response (patient adherence/persistence) to a lower out-of-pocket cost for insulin is unknown. Maximum patient Part D out-of-pocket set at $2,000.

Government 97

Government Manufacturing Prescription Competition 97

Pharmaceutical Technology

FEBRUARY 23, 2023

The TLR9 inhibitor is unique due to the rectal route of administration (ROA), which allows for local administration providing anti-inflammatory effects; however, this ROA could negatively affect compliance, as not all patients would prefer this method.

Marketing 59

Marketing Safety Competition Pharmaceutical 59

Clarify Health

FEBRUARY 6, 2024

That way, they can continue to grow membership and thrive against the competition. Prior Authorization While an important tool for health plans to control costs and prevent fraud, waste, and abuse, the prior authorization process is burdensome for providers, health plans, and patients.

Networking 52

Networking Insurance Government Management 52

Pharmaceutical Technology

JANUARY 10, 2023

Baxdrostat reduced systolic blood pressure in study subgroups, including Black/African American patients who make up approximately 81–89% of the hypertensive population in the US. The acquisition news came as the Annual JP Morgan Healthcare Conference was kickstarted in San Francisco on 9 January. Acquisition plans for 2023. Free Report.

Prospecting 98

Prospecting Pharma Pharmaceutical Competition 98

Pharmaceutical Technology

MAY 2, 2023

However, BK polyomavirus infections commonly occur in renal transplant patients and can cause serious complications such as hemorrhagic cystitis, BKV-associated nephropathy (BKVAN) and ureteric stenosis. Memo expects to potentially launch AntiBKV in 2025. Free Report How is the Biopharmaceutical industry evolving?

FDA 52

FDA Patients Recruitment Prospecting 52

Clarivate

AUGUST 20, 2024

In 2025, CMS will select another 15 Part D drugs for negotiations that will take effect in 2027. 1, 2024, following an IRA provision capping patients’ out-of-pocket costs at $35 per month. In highly competitive categories like diabetes, net price could be half of the list price. That compares to the $240.4

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52

Pharmaceutical Technology

APRIL 20, 2023

In March 2023, the company announced the screening of the trial’s first patient. DBV expects to share topline data from the study in H1 2025. The agency has since lifted the partial clinical hold following amendments to the study’s protocol in December 2022.

Food and Drug Administration 52

Food and Drug Administration FDA Safety Prospecting 52

Clarivate

DECEMBER 14, 2023

However, the PBM-focused strategy can result in higher out-of-pocket costs for patients who pay coinsurance for drugs based on WAC prices and may spur further criticism. Payers will continue to take ownership of providers, with numerous Blue plans staking a claim to settings where they can funnel patients to lower-cost care.

Marketing 52

Marketing Healthcare Healthcare Insurance 52